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ABSTRAK
Tujuan dari  penelitian ini  adalah  memanfaatkan antibodi poliklonal yang diproduksi dari  kuda 
(Equus caballus) lokal Indonesia  untuk membuat konjugat kit  ELISA pendeteksi  antigen permukaan 
virus  hepatitis  B  (VHB;  HBsAg).  Antibodi  poliklonal yang digunakan adalah  dari  kuda lokal yang 
diimunisasi berulang menggunakan HBsAg isolat Indonesia. Antibodi kemudian dikonjugasikan dengan 
enzim horseradish peroxidase dengan metode yang dimodifikasi dari Nakane dan Kawaoi. Uji aktivitas 
konjugat dilakukan dengan prinsip uji ELISA yang dikerjakan oleh peneliti dan juga oleh laboratorium 
independen.  Sebagai pembanding, digunakan konjugat ELISA HBsAg komersial. Hasil  penelitian ini 
menunjukkan bahwa antibodi yang diproduksi dari kuda lokal dapat digunakan untuk membuat konjugat 
dengan hasil yang sebanding dengan kit ELISA HBsAg komersial
Kata kunci: Kuda lokal, ELISA, antibodi poliklonal, hepatitis B, HBsAg
ABSTRACT
The aim of this study was to utilize the antibody produced using Indonesia local horses (Equus 
caballus) to make the conjugate of ELISA kit for detection of hepatitis B virus (HBV) surface antigen 
(HBsAg). The polyclonal antibodies were isolated and purified from local horses immunized repeatedly 
using isolated and purified HBsAg from Indonesia. The antibodies were conjugated with horseradish 
peroxidase by a modified method of Nakane and Kawaoi. The conjugate activities were performed using 
the  principle  of  ELISA test  conducted  by  the  researchers  as  well  as  by  independent  laboratory. 
Commercial conjugate for  HBsAg ELISA was used as a comparison study.  The results of this study 
indicated  that  the antibody produced from local  horses  can  be used  to  make conjugates  that  were 
comparable to commercial HBsAg ELISA kit.
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 INTRODUCTION
Up  to  now  the  hepatitis  B  virus  (HBV) 
remains a major cause of world health problems 
as a cause of significant morbidity and mortality 
(Zukerman  and  Zukerman,  2000).  Around  the 
world,  over  350  million  people  are  infected 
chronically with HBV, some of them will develop 
severe  liver  disease  including  cirrhosis  and 
hepatocellular carcinoma (Mulyanto  et al.,  2011, 
2012). The highest prevalence of HBV infection 
is generally found in Asia and Africa (Lee, 1997). 
In Indonesia the prevalence of HBV varies among 
the islands. It has been reported that HBV carrier 
rates among apparently healthy populations range 
from 4 to 20.3% (Khan et al., 2004; Mulyanto et  
al., 2008). Several efforts to prevent the spread of 
HBV  have  been  conducted  by  the  Indonesian 
government,  such  as  through  a  national 
vaccination  program  of  children  and  do  the 
screening  of  blood  donors  carried  out  by  the 
Indonesian Red Cross. 
To perform the screening test, some standard 
test  kits  or  methods  such  as  enzyme-linked 
immunosorbent  assay  (ELISA)  are  required. 
Several  standard  test  kits  including  ELISA are 
available in Indonesia. However, they mostly use 
components  that  are  imported  from  overseas 
which may lead to elevated production cost.  To 
anticipate the growing need, as well as to reduce 
our  dependency  on  imported  products,  it  is 
necessary to develop an ELISA kit against HBV 
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with raw materials produced locally.
Horse (Equus caballus) has long been used 
for  immunological  research  (Markel,  2007; 
Simon,  2007).  However  in  Indonesia  the 
utilization of local horses for diagnostic purposes 
is  still  limited.  In  this  paper  the  results  of  the 
utilization  of  local  horses  as  a  source  of 
polyclonal  antibodies  against  HBV,  which  were 
then used as raw materials to develop an ELISA 
conjugate,  are  reported.  It  is  expected  that  the 
conjugate  can  be  used  for  the  development  of 
ELISA kit for screening test of suspected samples 
being infected with HBV.
MATERIALS AND METHODS
Chemicals and Equipment
The  enzyme horseradish  peroxidase (HRP) 
Type  VI-A  (Lot  No.  118  K  76701),  ethylene 
glycol  anhydrous  99.8% (Lot  No.  0856AM),  1-
fluoro-2,4  dinitrobenzene  (FDNB;  Lot  No. 
0001451175), sodium meta-periodate (NaIO4; Lot 
No.  MKBCB727),  3,3,’,55-Tetramethylbenzidine 
(TMB) Substrate (T4444 #089K1699), tween 20, 
BSA,  were  purchased  from  Sigma,  USA,  and 
sodium  borohydride  (NaBH4)  obtained  from 
Merck. Other chemicals such as NaCl, KH2PO4, 
were of analytical grade.
ELISA  plates  used  were  Microtiterwells, 
12x8 (break apart) strips, 96 wells (SLP). Optical 
density  measurements  were made  on  a  Thermo 
Scientific  Multiscan  EX  Type  355 
spectrophotometer (Shanghai, China).
Polyclonal and Monoclonal Antibodies
Anti HBV polyclonal antibody is  produced 
locally  (West  Nusa  Tenggara  Hepatitis,  WNTH 
Laboratory).  It  was  derived  from hyperimmune 
sera  of  adult  local  Equus  caballus (Sumba  and 
Lombok female horses) which multi- immunized 
with  hepatitis  B  surface  antigens  (HBsAg) 
according  to  Mulyanto  (1991).  The  polyclonal 
antibody was a gift from Prof. Mulyanto and used 
as the main material to develop the conjugate. The 
monoclonal antibody (WNTH Laboratory Lot No. 
KO436) which is anti “a” determinant specific to 
HBsAg was  also  a  courtesy of  Prof.  Mulyanto. 
The  antibody  was  used  for  coating  the  ELISA 
plates. 
ELISA Kit Commercial
ELISA Kit  commercial  used  as  a  ‘gold’ 
standard  throughout  this  study  was  Wantai 
HBsAg ELISA Kit (Wantai, China). 
Conjugate Preparation
Conjugate  was  prepared  for  three  days 
continuously by coupling HRP-aldehyde solution 
with horse-anti HBsAg polyclonal antibody based 
on  Nakane  and  Kawaoi  (1974)  with  slight 
modifications.  On  day  one,  HRP-aldehyde 
solution  was  prepared  by  dissolving  a  5  mg  of 
HRP into 1.0 ml freshly made of 0.3  M sodium 
bicarbonate, pH 8.1. In to this solution, 0.1 ml of 
FDNB  (1-fluoro-2,4-dinitrobenzene)  in 
absolute  ethanol  was  added,  and  then  mixed 
gently for 1 hr at room temperature. Subsequently 
1.0  ml  of  0.08  M  NaI04 was  added and mixed 
gently for 30 min at room temperature. Following 
this, 1.0 ml of 0.16 M ethylene glycol was added, 
mixed gently for  1 hr  at room temperature, and 
dialyzed against  three 1-liter  changes of 0.01  M 
sodium carbonate buffer, pH 9.5, at 4°C. 
After  the  dialysis,  a  5  mg  of  horse  anti 
HBsAg-IgG was added to 3 mL of HRP-aldehyde 
solution  and  mixed  gently  for  3  hr  at  room 
temperature.  After  that,  5  mg  of  NaBH4 was 
added and let stand for 3 hr at room temperature, 
then dialyzed at 4°C against PBS overnight. 
Finally,  the  solution  was  purified  by 
applying the solution to a 60 x 1.5 cm Sephacryl-
200 HR column (Pharmacia, Sweden) equilibrated 
in PBS and the absorbance of  the fractions was 
read  at  280  nm.  The  main  peak  fractions  was 
pooled and designated as HRP labeled horse-anti 
HBsAg  IgG  polyclonal  antibody  and  used  for 
conjugate of the in-house HBsAg ELISA. 
ELISA Plates Preparation
ELISA plates  were prepared by a  standard 
procedure by coating  the wells  with 5µg/mL of 
mouse-anti  HBsAg  monoclonal  antibody  in 
carbonate buffer pH 9.5 at 100 µL per well and 
left  overnight  at  4°C.  Afterward,  plates  were 
blocked with 1% BSA-PBS, 300 µL/well for 3 h 
at  room  temperature  and  washed  3  times  with 
PBS  containing  0.05%  Tween  20  (PBS-T). 
Following washing, plates were dried and kept in 
a foil sachet with desiccate gel.  The plates were 
stored in 4°C until used.
Conjugate Tests
The principle of conjugate test that had been 
developed  from  horse serum in  this  study  was 
based  on  immunological  reactions  between  the 
primary  antibody  coated  to  the  plate  and  the 
antigen in the sample, and then the reaction to the 
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conjugate.  To that  end,  50 µL of  three different 
(low,  medium,  and  high)  concentrations  of  in-
house HBsAg positive or negative standards were 
added  into  each  well  of  plates  coated  with  the 
primary antibody. Furthermore into the respective 
wells were added 50 µL of conjugate. The plate 
was then sealed and incubated for 60 min at 37ºC. 
After  incubation,  the  plate  was  washed  with  a 
washing solution  of  300  µL per  well.  Washing 
was  performed  5  times,  and  50  µL  of  TMB 
substrate was added into each well subsequently. 
Following incubation for 15 min in a dark room at 
37ºC, the reaction was stopped by adding 50 µL 
of 1 N sulfuric acid into the respective wells. The 
reaction  was  then  read  using  an  ELISA 
photoreader  at  a  450  nm  wavelength. 
Comparisons are performed simultaneously using 
a  commercial  ELISA Kit  HBsAg.  In  addition, 
comparative  test  was  also  conducted  by  an 
independent  laboratory  with  a  commercial  kit 
using a known concentration of HBsAg standard 
to  obtain  as  objective  result  as  possible.  The 
HBsAg concentrations  used  were 0,  1.24,  5.43, 
24.10, 107 and 465 IU/mL. 
Data Analysis
The  data  obtained  were  compared 
descriptively  to  give  an  idea  of  the  quality  of 
conjugated  antibody  produced  in  this  study. 
Quantitative data regarding the ELISA tests were 
tabulated and analyzed according to Drouet et al. 
(2003), and Depamede and Kisworo (2011).
RESULTS AND DISCUSSION
Based  on  historical  records,  the horse  has 
long  been  used  for  research  in  the  field  of 
immunology. Even since scientists have not been 
able  to  discover  about  the  antigen-antibody 
reactions, Emil von Behring had successfully used 
horse  serum as  a  serum therapy for  diphtheria 
(Stiehm and Johnston, 2005; Raju, 2006, Simon, 
2007). Nowadays horses still been used for serum 
therapy purposes (Bunning et al., 2002; de Cuetos 
et al., 2011), and for diagnostic development such 
as diagnostic for HBsAg. In this study the purified 
polyclonal  antibody  produced  in  local  horses 
using  HBsAg  of  Indonesia  origin  (Mulyanto, 
1991)  was  used to make conjugates  for  HBsAg 
ELISA.  Preparation  of  the  conjugates  includes 
several steps such as binding of HRP enzyme as a 
marker onto the polyclonal antibodies. Following 
the binding, the conjugate was purified by means 
of  size-exlusion  column method.  In  the present 
study the binding and purification methods were 
performed  by  using  the  classical  method 
according  to  Nakane  and  Kawaoi  (1974)  with 
some modifications, and a representative result is 
presented in Figure 1.  The main peak (fractions 
from minute 55 to minute 75) is the image of the 
binding  reaction  between  the  antibody  and  the 
HRP  enzyme.  The  pooled  fractions  was  then 
defined  as  the  in-house  conjugate  and  used  in 
subsequent experiments.
To  find  out  whether  the  developed 
conjugates could  be used  as a  reagent to detect 
HBsAg,  the  conjugates  were  tested  against  a 
negative  and  three  defined  in-house  positive 
standard samples.  The test  results  are shown in 
Figure  2.  It  can  be  seen  in  Figure  2  that  the 
conjugates  produced  in  this  study  gave 
comparable results to existing commercial kits (P 
>0.05). Furthermore, test results carried out by an 
anonymous independent laboratory (Figure 3) was 
also revealed that the conjugates produced in this 
study have  a  comparable  quality  to  that  of  the 
commercial  conjugate  against  known 
concentration  of  HBsAg  standards  used  to 
perform the comparison tests.  Pattern of  curves 
presented  in  Figures  2  and 3  are  in  agreement 
with the results of Karakus et al. (2007).
According  to  Gerritse  et  al.  (1991),  key 
points to consider when developing a conjugate is 
process  itself  should  not  affect  the  activity  of 
enzymes and antibodies  used.  The results of the 
present study indicated that the conjugate (pooled 
fractions  of  the  main  peak,  Figure  1)  provides 
immunological  and enzymatic  reactions  that  are 
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Figure 1. Representation of Chromatogram of 5 mg 
Horse  Anti  HBsAg  IgG  Conjugated  with  5  mg 
HRP Activated by 0.08 M NaIO4 as Modified from 
Nakane and Kawaoi (1974) 
uV
Min
equivalent to a similar reaction on a commercial 
conjugate  (Figure  2).  Furthermore,  the 
independent  test  results  as  shown  in  Figure  3 
reinforced  that  the  conjugates  produced  in  this 
study gave reliable results. Even so, when it was 
seen in Figures 2 and 3 there was a tendency that 
the  conjugates  produced  in  this  study  (filled 
circles) was still below the commercial conjugate 
(open circles). Shin and Heo (2000) asserted that 
in  addition  to  sensitivity  and  specificity  of  a 
diagnostic kit, the other values that  need to also 
consider is detection limit and its reproducibility. 
For those reasons, the results of the present study 
still need to be followed up further.
Overall  these  results  suggest  that  the 
antibodies produced by utilizing the local horses 
to  develop  the  conjugate  ELISA,  can  provide 
comparable  results  to  conjugates  that  available 
commercially.
Utilization of Indonesia germ plasma is very 
important,  especially  in  the  efforts  to  develop 
vaccines and immunodiagnostics such as against 
HBV,  especially  to  improve  the  immune 
specificity of  the vaccine or  the kit.  Recently it 
has  been  reported  that  in  Indonesia  some  new 
HBV genotypes have been elucidated (Lusida  et 
al., 2008,  Mulyanto  et  al., 2009,  2010,  2011, 
2012).  This  means  that  efforts  to  prevent  the 
spread  of  HBV  in  Indonesia  will  be  more 
effective  if  we  can  provide  the  components  to 
develop  diagnostic  kits  derives  from  the  local 
germ  plasma.  This  should  become  a  serious 
concern for Indonesia with a population of more 
than  200  million  people  with  the  HBV carrier 
rates are 4-20.3% (Khan et al., 2004; Mulyanto et 
al., 2008).
CONCLUSION 
This  study  shows  that  antibody  generated 
using the local horses can be utilized to develop 
test  kit  against  infectious  diseases  such  as 
Hepatitis B with feasible results. However, further 
studies are still required to improve it sensitivity, 
specificity, reproducibility and stability as needed 
by a diagnostic kit.
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